BiotechTube

Selinexor + Matching Placebo for selinexor

Phase 3Recruiting
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometrial Cancer

Conditions

Endometrial Cancer

Trial Timeline

Apr 18, 2023 → Jan 1, 2028

NCT ID
NCT05611931

About Selinexor + Matching Placebo for selinexor

Selinexor + Matching Placebo for selinexor is a phase 3 stage product being developed by Karyopharm Therapeutics for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05611931. Target conditions include Endometrial Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT05611931Phase 3Recruiting
NCT03555422Phase 3Active

Competing Products

20 competing products in Endometrial Cancer

See all competitors
ProductCompanyStageHype Score
Atezolizumab - 28 Day Cycle + Bevacizumab + Ipatasertib + Talazoparib + Trastuzumab emtansine + Tiragolumab + Atezolizumab - 21 Day Cycle + Inavolisib + Letrozole + Giredestrant + AbemaciclibEli LillyPhase 1/2
41
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
44
Sodium Cridanimod + progestin therapyXenetic BiosciencesPhase 2
44
Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + GedatolisibeFFECTOR TherapeuticsPhase 2
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + DocetaxelDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan + ChemotherapyDaiichi SankyoPhase 3
77
Datopotamab deruxtecan (Dato-DXd) + Capecitabine + 5-Fluorouracil + Volrustomig + Carboplatin + Bevacizumab + Rilvegostomig + Prednisone/ prednisolone + CisplatinDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Enfortumab VedotinAstellas PharmaPhase 2
52
Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3
77
LenvatinibEisaiPhase 2
52
Pembrolizumab + Lenvatinib + Paclitaxel + DoxorubicinEisaiPhase 3
77
Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3
77
E7386 + Lenvatinib + Doxorubicin + PaclitaxelEisaiPhase 1/2
41
Abemaciclib + LetrozoleEli LillyPhase 2
52
Abemaciclib + Anastrozole + LetrozoleEli LillyPhase 2
52
LY3023414Eli LillyPhase 2
52
arzoxifene hydrochlorideEli LillyPhase 2
52
Abemaciclib + Letrozole + PembrolizumabEli LillyPhase 2
52

Other Products from Karyopharm Therapeutics

Selinexor + Matching placebo for selinexorPhase 3
69
Selinexor + Selinexor + RuxolitinibPhase 3
69
Selinexor + Elotuzumab + Pomalidomide + Dexamethasone OralPhase 3
69
Selinexor + Bortezomib + DexamethasonePhase 3
69
Selinexor + PlaceboPhase 2/3
57